These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25493579)

  • 1. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex -  pharmacological treatment using mTOR inhibitors].
    Zitterbart K
    Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
    Wheless JW; Klimo P
    J Child Neurol; 2014 Nov; 29(11):1562-71. PubMed ID: 24105488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
    Ebrahimi-Fakhari D; Franz DN
    Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with Mammalian target of rapamycin inhibitors.
    Prato G; Mancardi MM; Baglietto MG; Janis S; Vercellino N; Rossi A; Consales A; Raso A; Garrè ML
    J Child Neurol; 2014 Sep; 29(9):NP54-7. PubMed ID: 24056156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
    Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
    Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberous sclerosis complex.
    DiMario FJ; Sahin M; Ebrahimi-Fakhari D
    Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract]   [Full Text] [Related]  

  • 9. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
    Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
    Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Major P
    Aging (Albany NY); 2011 Mar; 3(3):189-91. PubMed ID: 21415462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
    Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
    N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
    Goyer I; Dahdah N; Major P
    Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.
    Roth J; Roach ES; Bartels U; Jóźwiak S; Koenig MK; Weiner HL; Franz DN; Wang HZ
    Pediatr Neurol; 2013 Dec; 49(6):439-44. PubMed ID: 24138953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.
    Skalicky AM; Rentz AM; Liu Z; Wheless JW; Pelletier CL; Dunn DW; Frost MD; Nakagawa J; Magestro M; Prestifilippo J; Pashos C
    J Child Neurol; 2015 Apr; 30(5):563-9. PubMed ID: 24667738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation.
    Prabowo AS; Anink JJ; Lammens M; Nellist M; van den Ouweland AM; Adle-Biassette H; Sarnat HB; Flores-Sarnat L; Crino PB; Aronica E
    Brain Pathol; 2013 Jan; 23(1):45-59. PubMed ID: 22805177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.